Identifiers | |
---|---|
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
UNII | |
ChEMBL | |
Chemical and physical data | |
Formula | C16H21NO5S |
Molar mass | 339.41 g·mol−1 |
3D model ( JSmol) | |
| |
|
Moguisteine is a non-narcotic, peripherally acting antitussive. [1] In a small double-blind, randomized controlled trial, 200 mg of moguisteine suspension taken 3 times daily significantly reduced the frequency of coughing in patients with COPD, compared to placebo. [2] It has also been studied in small trials in comparison to codeine [3] and dextromethorphan, [4] and has similar efficacy to both. It has not been approved for use in the United States. [5]
It was discovered by searching for expectorants of the thiazolidine class, when compounds with a cough suppressant effect were accidentally found and moguisteine was selected as the most effective and safest representative of the class. [6] Its mechanism of action may be the activation of ATP-sensitive potassium channels. [7]
Identifiers | |
---|---|
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
UNII | |
ChEMBL | |
Chemical and physical data | |
Formula | C16H21NO5S |
Molar mass | 339.41 g·mol−1 |
3D model ( JSmol) | |
| |
|
Moguisteine is a non-narcotic, peripherally acting antitussive. [1] In a small double-blind, randomized controlled trial, 200 mg of moguisteine suspension taken 3 times daily significantly reduced the frequency of coughing in patients with COPD, compared to placebo. [2] It has also been studied in small trials in comparison to codeine [3] and dextromethorphan, [4] and has similar efficacy to both. It has not been approved for use in the United States. [5]
It was discovered by searching for expectorants of the thiazolidine class, when compounds with a cough suppressant effect were accidentally found and moguisteine was selected as the most effective and safest representative of the class. [6] Its mechanism of action may be the activation of ATP-sensitive potassium channels. [7]